(EMAILWIRE.COM, October 09, 2018 ) According to the new market research report “Glycomics/Glycobiology Market by Product (Enzymes (Glycosyltransferase, Glycosidase), Instruments (HPLS, Mass Spectrometry, MALDITOF), Kits & Reagents (Glycoproteins)), Application (Diagnostic, Drug Discovery, Oncology), End User - Global Forecast to 2021", published by MarketsandMarkets™, The global glycomics/glycobiology market is expected to reach USD 1,211.4 Million by 2021 from USD 649.5 Million in 2016, at a CAGR of 13.3%. The market is segmented based on product, application, end user, and region.

Don’t miss out on business opportunities in Glycomics/Glycobiology Market. Speak to our analyst and gain crucial industry insights that will help your business grow: http://bit.ly/2RoX6om
Early buyers will receive 10% customization on reports.

The global glycomics/glycobiology market is expected to reach USD 1,211.4 Million by 2021 from USD 649.5 Million in 2016, at a CAGR of 13.3% during the forecast period. Factors such as increasing government and private funding for glycomics and proteomics research and growing R&D expenditure by pharmaceutical and biotechnology companies are the key drivers for the growth of this market.

The global glycomics/glycobiology market is broadly segmented into product, application, end user, and region. On the basis of product, the market is segmented into enzymes, instruments, kits, and reagents. In 2016, the enzymes segment is expected to account for the largest share of the global glycomics/glycobiology market. The enzymes segment is further categorized into glycosidases, glycosyltransferases, neuraminidases, sialyltransferases, and other enzymes. In 2016, the glycosidases segment is expected to account for the largest share of the market owing to its consumable nature, vast applications of glycosidase enzymes in R&D, and drug development processes.

On the basis of application, the market is segmented into diagnostics, drug discovery and development, immunology, oncology, and other applications. In 2016, the drug discovery and development segment is expected to command the largest share and grow at the highest CAGR during the forecast period. The large share and high growth in this segment can be attributed to the increase in R&D activities for the development of novel drugs and therapies.

On the basis of end user, the market is segmented into academic research institutes, pharmaceutical & biotechnology companies, and contract research organizations. In 2016, the academic research institutes segment is expected to account for the largest share of the market. This growth can be attributed to the rising availability of funding for life science research.

Browse and in-depth TOC on “Glycomics/Glycobiology Market”
91 - Tables

32 - Figures

158 - Pages 

View more detailed TOC @ https://www.marketsandmarkets.com/Market-Reports/glycobiology-market-132685525.html

On the basis of region, the market was dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). In 2015, North America accounted for the largest share of the market, while Asia witnessed the highest growth rate mainly due to increasing commercialization of pharmaceutical and biotechnology research, increasing awareness about personalized medicine, and rising importance of companion diagnostics.

Major players in the glycomics/glycobiology market include are Agilent Technologies (U.S.), Bruker Corporation (U.S.), Danaher Corporation (U.S.), New England Biolabs (U.S.), ProZyme, Inc. (U.S.), Shimadzu Corporation (Japan), Merck KGaA (Germany), Takara Bio, Inc. (Japan), Thermo Fisher Scientific (U.S.), and Waters Corporation (U.S.).

Request for Free Sample Report @ http://bit.ly/2BX7QVO

Browse Adjacent Markets @ Biotechnology Market Research Reports & Consulting
About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:

Mr. Shelly Singh

MarketsandMarkets™ INC.
630 Dundee Road

Suite 430

Northbrook, IL 60062

USA : 1-888-600-6441

Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/glycobiology-market.asp

Visit Our Website: https://www.marketsandmarkets.com